BR9713479A - Preparação farmacêutica compreendendo ácido eicosapentaenóico e/ou ácido estearidÈnico. - Google Patents
Preparação farmacêutica compreendendo ácido eicosapentaenóico e/ou ácido estearidÈnico.Info
- Publication number
- BR9713479A BR9713479A BR9713479-1A BR9713479A BR9713479A BR 9713479 A BR9713479 A BR 9713479A BR 9713479 A BR9713479 A BR 9713479A BR 9713479 A BR9713479 A BR 9713479A
- Authority
- BR
- Brazil
- Prior art keywords
- acid
- pharmaceutical preparation
- stearidonic
- eicosapentaenoic
- eicosapentaenoic acid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9621294.9A GB9621294D0 (en) | 1996-10-11 | 1996-10-11 | Fatty acid treatment |
GBGB9626062.5A GB9626062D0 (en) | 1996-10-11 | 1996-12-16 | Fatty acid treatment |
PCT/GB1997/002738 WO1998016216A1 (en) | 1996-10-11 | 1997-10-07 | Pharmaceutical preparation comprising eicosapentaenoic acid and/or stearidonic acid |
Publications (1)
Publication Number | Publication Date |
---|---|
BR9713479A true BR9713479A (pt) | 2000-04-11 |
Family
ID=26310221
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR9713479-1A BR9713479A (pt) | 1996-10-11 | 1997-10-07 | Preparação farmacêutica compreendendo ácido eicosapentaenóico e/ou ácido estearidÈnico. |
Country Status (25)
Country | Link |
---|---|
US (5) | US6331568B1 (pt) |
EP (1) | EP0956013B1 (pt) |
JP (1) | JP4151853B2 (pt) |
KR (2) | KR20060061409A (pt) |
CN (1) | CN1109543C (pt) |
AT (1) | ATE236627T1 (pt) |
AU (1) | AU731692C (pt) |
BR (1) | BR9713479A (pt) |
CA (1) | CA2268257C (pt) |
CZ (1) | CZ293704B6 (pt) |
DE (1) | DE69720787T2 (pt) |
DK (1) | DK0956013T3 (pt) |
ES (1) | ES2195175T3 (pt) |
HK (1) | HK1020316A1 (pt) |
ID (1) | ID21473A (pt) |
IL (1) | IL129367A0 (pt) |
IS (1) | IS2180B (pt) |
NO (1) | NO326926B1 (pt) |
NZ (1) | NZ334852A (pt) |
PL (1) | PL190181B1 (pt) |
PT (1) | PT956013E (pt) |
SK (1) | SK285210B6 (pt) |
TR (1) | TR199900786T2 (pt) |
TW (1) | TW429145B (pt) |
WO (1) | WO1998016216A1 (pt) |
Families Citing this family (109)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20060061409A (ko) * | 1996-10-11 | 2006-06-07 | 스카리스타 리미티드 | 에이코사펜타엔산 및/또는 스테아리돈산을 포함하여이루어지는 오일 |
ATE320803T1 (de) * | 1998-01-28 | 2006-04-15 | Warner Lambert Co | Verfahren zur behandlung von alzheimerschen krankheit |
US7138431B1 (en) | 1998-02-23 | 2006-11-21 | Wake Forest University | Dietary control of arachidonic acid metabolism |
US6107334A (en) | 1998-02-23 | 2000-08-22 | Wake Forest University | Dietary control of arachidonic acid metabolism |
FR2788437B1 (fr) * | 1999-01-14 | 2006-08-11 | Inst Rech Biolog Sa | Nouvelle utilisation de phospholipides d'origine vegetale et animale en therapeutique nutritionnelle |
AU2006201772B2 (en) * | 1999-01-27 | 2010-02-04 | Amarin Neuroscience Limited | Highly purified ethyl EPA and other EPA derivatives for psychiatric and neurological disorders |
GB9901808D0 (en) * | 1999-01-27 | 1999-03-17 | Scarista Limited | Drugs for treatment of psychiatric and brain disorders |
GB9901809D0 (en) | 1999-01-27 | 1999-03-17 | Scarista Limited | Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes |
GB9904895D0 (en) * | 1999-03-03 | 1999-04-28 | Scarista Limited | Regulators of coenzyme-A-independent transacylase as psychotropic drugs |
ES2425114T3 (es) * | 2000-03-16 | 2013-10-11 | The Mclean Hospital Corporation | CDP-colina y uridina para el tratamiento del abuso del acohol |
IL142535A0 (en) * | 2001-04-11 | 2002-03-10 | Yeda Res & Dev | Pharmaceutical compositions for the treatment of inflammation |
IL142536A0 (en) * | 2001-04-11 | 2002-03-10 | Yeda Res & Dev | Carriers for therapeutic preparations for treatment of t-cell mediated diseases |
WO2002092779A2 (en) * | 2001-05-17 | 2002-11-21 | Pilot Therapeutics, Inc. | Method for enriching tissues in long chain polyunsaturated fatty acids |
DE60221287T4 (de) | 2001-11-08 | 2009-06-25 | Atrium Medical Corp. | Intraluminale vorrichtung mit einer ein therapeutisches-mittel enthaltenden beschichtung |
NL1019368C2 (nl) | 2001-11-14 | 2003-05-20 | Nutricia Nv | Preparaat voor het verbeteren van receptorwerking. |
US8987263B2 (en) * | 2002-10-10 | 2015-03-24 | Meir Shinitzky | Basic esters of fatty alcohols and their use as anti-inflammatory or immunomodulatory agents |
GB0311081D0 (en) * | 2003-05-14 | 2003-06-18 | Btg Internat Limted | Treatment of neurodegenerative conditions |
CH698539A8 (de) | 2003-08-18 | 2009-10-15 | Btg Int Ltd | Verbindungen mit ungesättigten Fettsäureresten zur Herstellung von Medikamenten zur Behandlung von multipler Sklerose. |
JP2007508315A (ja) * | 2003-10-08 | 2007-04-05 | ザ マクレーン ホスピタル コーポレーション | ω−3脂肪酸を含む組み合わせを用いて、精神障害、物質乱用障害、および他の障害を治療する方法 |
US20050113449A1 (en) * | 2003-10-08 | 2005-05-26 | Renshaw Perry F. | Enhanced efficacy of omega-3 fatty acid therapy in the treatment of psychiatric disorders and other indications |
EP1713463A4 (en) * | 2004-01-19 | 2009-03-18 | Martek Biosciences Corp | REELIN DYSFUNCTION OR DICTION AND ASSOCIATED TECHNIQUES |
ITMI20040069A1 (it) * | 2004-01-21 | 2004-04-21 | Tiberio Bruzzese | Uso di composizioni di acidi grassi n-3 ad elevata concentrazione per il trattamento di disturbi del sistema nervoso centrale |
US7022713B2 (en) * | 2004-02-19 | 2006-04-04 | Kowa Co., Ltd. | Hyperlipemia therapeutic agent |
US20050266051A1 (en) * | 2004-05-27 | 2005-12-01 | The Procter & Gamble Company | Pet food compositions and methods |
EP1765364A4 (en) * | 2004-06-10 | 2010-09-22 | Mclean Hospital Corp | PYRIMIDINES, SUCH AS Z: B: CYTIDINE, IN THE TREATMENT OF PATIENTS WITH BIPOLAR DISORDER |
WO2005122767A1 (en) * | 2004-06-10 | 2005-12-29 | Mclean Hospital Corporation | Pyrimidines, such as uridine, in treatments for patients with bipolar disorder |
EP1784199A4 (en) * | 2004-08-11 | 2010-06-23 | Mclean Hospital Corp | COMPOUNDS FOR TREATING MARIHUANA DEPENDENCE, DEDUCTION AND CONSUMPTION |
US9801982B2 (en) | 2004-09-28 | 2017-10-31 | Atrium Medical Corporation | Implantable barrier device |
US9000040B2 (en) | 2004-09-28 | 2015-04-07 | Atrium Medical Corporation | Cross-linked fatty acid-based biomaterials |
US20090011116A1 (en) * | 2004-09-28 | 2009-01-08 | Atrium Medical Corporation | Reducing template with coating receptacle containing a medical device to be coated |
US8312836B2 (en) | 2004-09-28 | 2012-11-20 | Atrium Medical Corporation | Method and apparatus for application of a fresh coating on a medical device |
US8367099B2 (en) | 2004-09-28 | 2013-02-05 | Atrium Medical Corporation | Perforated fatty acid films |
US9801913B2 (en) | 2004-09-28 | 2017-10-31 | Atrium Medical Corporation | Barrier layer |
WO2006036970A2 (en) * | 2004-09-28 | 2006-04-06 | Atrium Medical Corporation | Method of thickening a coating using a drug |
US8263102B2 (en) * | 2004-09-28 | 2012-09-11 | Atrium Medical Corporation | Drug delivery coating for use with a stent |
US9012506B2 (en) | 2004-09-28 | 2015-04-21 | Atrium Medical Corporation | Cross-linked fatty acid-based biomaterials |
US7550286B2 (en) * | 2004-11-04 | 2009-06-23 | E. I. Du Pont De Nemours And Company | Docosahexaenoic acid producing strains of Yarrowia lipolytica |
US20090318394A1 (en) * | 2004-11-19 | 2009-12-24 | Julie Nauroth | Long Chain Polyunsaturated Fatty Acids and Methods of Making and Using the Same |
KR20070090928A (ko) * | 2004-11-19 | 2007-09-06 | 마텍 바이오싸이언스스 코포레이션 | 장쇄 다가불포화 지방산으로부터의 옥시리핀, 및 이의 제조방법 및 사용 방법 |
US7893106B2 (en) * | 2004-11-19 | 2011-02-22 | Martek Biosciences, Corporation | Oxylipins from stearidonic acid and γ-linolenic acid and methods of making and using the same |
GB0425932D0 (en) * | 2004-11-25 | 2004-12-29 | Btg Int Ltd | Structured phospholipids |
GB2421909A (en) * | 2004-12-23 | 2006-07-12 | Laxdale Ltd | Pharmaceutical compositions comprising EPA and methods of use |
GB0504362D0 (en) | 2005-03-02 | 2005-04-06 | Btg Int Ltd | Cytokine modulators |
GB0504333D0 (en) * | 2005-03-02 | 2005-04-06 | Btg Int Ltd | Treatment of cytokine dysregulation |
CN103211807A (zh) * | 2005-07-08 | 2013-07-24 | Dsmip资产公司 | 用于治疗痴呆和前痴呆相关病症的多不饱和脂肪酸 |
US9278161B2 (en) | 2005-09-28 | 2016-03-08 | Atrium Medical Corporation | Tissue-separating fatty acid adhesion barrier |
US9427423B2 (en) | 2009-03-10 | 2016-08-30 | Atrium Medical Corporation | Fatty-acid based particles |
CA2626030A1 (en) | 2005-10-15 | 2007-04-26 | Atrium Medical Corporation | Hydrophobic cross-linked gels for bioabsorbable drug carrier coatings |
CA2634139C (en) * | 2005-12-20 | 2015-06-23 | Cenestra, Llc. | Omega 3 fatty acid formulations |
EP1983977A4 (en) * | 2006-01-31 | 2011-11-30 | Martek Biosciences Corp | OXYLIPINES FROM STEARIDONIC ACID AND GAMMA-LINOLIC ACID AND METHOD FOR THE PRODUCTION AND USE THEREOF |
WO2008057328A2 (en) | 2006-11-06 | 2008-05-15 | Atrium Medical Corporation | Tissue separating device with reinforced support for anchoring mechanisms |
US9492596B2 (en) | 2006-11-06 | 2016-11-15 | Atrium Medical Corporation | Barrier layer with underlying medical device and one or more reinforcing support structures |
US20100130611A1 (en) * | 2006-12-20 | 2010-05-27 | Cenestra Llc | Omega 3 fatty acid formulations |
CN101663031A (zh) * | 2007-02-20 | 2010-03-03 | 马泰克生物科学公司 | 来自长链多不饱和脂肪酸的氧脂素及其制备方法和使用方法 |
WO2008106092A1 (en) * | 2007-02-26 | 2008-09-04 | Yeda Research And Development Co. Ltd. | Enantiomers of amino-phenyl-acetic acid octadec- 9- (z) enyl ester, their salts and their uses |
US20080221115A1 (en) * | 2007-02-26 | 2008-09-11 | Liat Hayardeny-Nisimov | Use of long-chain alcohol derivatives for the treatment of alopecia areata |
US8323935B2 (en) * | 2007-10-03 | 2012-12-04 | E I Du Pont De Nemours And Company | Optimized strains of Yarrowia lipolytica for high eicosapentaenoic acid production |
CA2704371A1 (en) * | 2007-11-01 | 2009-05-07 | Wake Forest University School Of Medicine | Compositions and methods for prevention and treatment of mammalian diseases |
US8343753B2 (en) * | 2007-11-01 | 2013-01-01 | Wake Forest University School Of Medicine | Compositions, methods, and kits for polyunsaturated fatty acids from microalgae |
WO2009086281A1 (en) * | 2007-12-21 | 2009-07-09 | Martek Biosciences Corporation | Method for preparation of oxylipins |
US20100041621A1 (en) * | 2008-08-15 | 2010-02-18 | Perry Renshaw | Methods and compositions for improving cognitive performance |
DK2334295T3 (en) | 2008-09-02 | 2017-10-09 | Amarin Pharmaceuticals Ie Ltd | PHARMACEUTICAL COMPOSITION COMPREHENSIVE EICOSAPENTAIC ACID AND NICOTIC ACID AND PROCEDURES FOR USING SAME |
AU2015203289B2 (en) * | 2008-09-09 | 2017-03-16 | Orygen Research Centre | Prevention of psychotic disorders and/or treatment of psychotic symptoms |
US20110166229A1 (en) * | 2008-09-09 | 2011-07-07 | Orygen Research Centre | Prevention of psychotic disorders and/or treatment of psychotic symptoms |
US8060617B2 (en) * | 2008-12-19 | 2011-11-15 | Cisco Technology, Inc. | Reserving network resources during scheduling of meeting event |
LT3037089T (lt) | 2009-02-10 | 2020-01-10 | Amarin Pharmaceuticals Ireland Limited | Eikozapentaeno rūgšties etilo esteris skirtas hipertriglicidemijai gydydti |
GB0904300D0 (en) | 2009-03-12 | 2009-04-22 | Amarin Neuroscience Ltd | Essential fatty acid compounds |
WO2010127103A1 (en) | 2009-04-29 | 2010-11-04 | Amarin Pharma, Inc. | Stable pharmaceutical composition and methods of using same |
AU2010241567B2 (en) | 2009-04-29 | 2013-10-31 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical compositions comprising EPA and a cardiovascular agent and methods of using the same |
US8455472B2 (en) | 2009-06-15 | 2013-06-04 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
US20110038910A1 (en) | 2009-08-11 | 2011-02-17 | Atrium Medical Corporation | Anti-infective antimicrobial-containing biomaterials |
KR101798670B1 (ko) | 2009-09-23 | 2017-11-16 | 아마린 코포레이션 피엘씨 | 오메가-3 지방산 및 스타틴의 히드록시-유도체를 포함하는 제약 조성물 및 그의 사용 방법 |
US8372465B2 (en) | 2010-02-17 | 2013-02-12 | Bunge Oils, Inc. | Oil compositions of stearidonic acid |
RU2728825C2 (ru) * | 2010-03-04 | 2020-07-31 | Амарин Фармасьютикалз Айрлэнд Лимитед (Апил) | Композиции и способы лечения и/или предотвращения сердечно-сосудистого заболевания |
EP2593141B1 (en) | 2010-07-16 | 2018-07-04 | Atrium Medical Corporation | Composition and methods for altering the rate of hydrolysis of cured oil-based materials |
US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
NZ727980A (en) | 2010-11-29 | 2018-08-31 | Amarin Pharmaceuticals Ie Ltd | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
WO2012083034A1 (en) * | 2010-12-15 | 2012-06-21 | Louis Sanfilippo | Modulation of neurotrophic factors by omega-3 fatty acid formulations |
US8951514B2 (en) | 2011-02-16 | 2015-02-10 | Pivotal Therapeutics Inc. | Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels |
US9119826B2 (en) | 2011-02-16 | 2015-09-01 | Pivotal Therapeutics, Inc. | Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels |
US8715648B2 (en) | 2011-02-16 | 2014-05-06 | Pivotal Therapeutics Inc. | Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics |
US8952000B2 (en) | 2011-02-16 | 2015-02-10 | Pivotal Therapeutics Inc. | Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events |
EP2540292A1 (en) * | 2011-06-28 | 2013-01-02 | Nestec S.A. | DHA and EPA in the reduction of oxidative stress |
US20130131170A1 (en) | 2011-11-07 | 2013-05-23 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
US11291643B2 (en) | 2011-11-07 | 2022-04-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
EP2800469B1 (en) | 2012-01-06 | 2021-08-25 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering levels of high-sensitivity (hs-crp) in a subject |
US9867880B2 (en) | 2012-06-13 | 2018-01-16 | Atrium Medical Corporation | Cured oil-hydrogel biomaterial compositions for controlled drug delivery |
RS61557B1 (sr) | 2012-06-29 | 2021-04-29 | Amarin Pharmaceuticals Ie Ltd | Postupci za smanjenje rizika od kardiovaskularnog događaja kod pacijenta na terapiji statinom primenom etil estra eikozapentaenske kiseline |
WO2014074552A2 (en) | 2012-11-06 | 2014-05-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy |
US9814733B2 (en) | 2012-12-31 | 2017-11-14 | A,arin Pharmaceuticals Ireland Limited | Compositions comprising EPA and obeticholic acid and methods of use thereof |
US20140187633A1 (en) | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
US9452151B2 (en) | 2013-02-06 | 2016-09-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein C-III |
US9624492B2 (en) | 2013-02-13 | 2017-04-18 | Amarin Pharmaceuticals Ireland Limited | Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof |
US9662307B2 (en) | 2013-02-19 | 2017-05-30 | The Regents Of The University Of Colorado | Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof |
US9283201B2 (en) | 2013-03-14 | 2016-03-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for treating or preventing obesity in a subject in need thereof |
US20140271841A1 (en) | 2013-03-15 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
US10966968B2 (en) | 2013-06-06 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof |
US20150065572A1 (en) | 2013-09-04 | 2015-03-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing prostate cancer |
US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
EP3102227A4 (en) | 2014-02-07 | 2017-09-27 | University Of Utah Research Foundation | Combination of creatine, an omega-3 fatty acid, and citicoline |
US10561631B2 (en) | 2014-06-11 | 2020-02-18 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing RLP-C |
US10172818B2 (en) | 2014-06-16 | 2019-01-08 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
WO2016063959A1 (ja) * | 2014-10-24 | 2016-04-28 | 日油株式会社 | 環状ベンジリデンアセタールリンカーを有する抗体―薬物複合体 |
ES2607715B1 (es) * | 2015-10-01 | 2018-01-17 | Solutex Na, Lcc | Proceso para la preparación y estabilización de emulsiones con omega-3 mediante redes cristalinas isométricas de derivados de celulosa |
US10406130B2 (en) | 2016-03-15 | 2019-09-10 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
US10966951B2 (en) | 2017-05-19 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject having reduced kidney function |
US11058661B2 (en) | 2018-03-02 | 2021-07-13 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L |
WO2020068163A1 (en) | 2018-09-24 | 2020-04-02 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of cardiovascular events in a subject |
KR20240012390A (ko) | 2021-04-21 | 2024-01-29 | 애머린 파마슈티칼스 아일랜드 리미티드 | 심부전의 위험을 감소시키는 방법 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1239587A (en) | 1983-10-24 | 1988-07-26 | David Rubin | Combined fatty acid composition for lowering blood cholestrol and triglyceride levels |
GB8601915D0 (en) * | 1986-01-27 | 1986-03-05 | Efamol Ltd | Pharmaceutical compositions |
US5252333A (en) * | 1987-04-27 | 1993-10-12 | Scotia Holdings Plc | Lithium salt-containing pharmaceutical compositions |
GB8813766D0 (en) * | 1988-06-10 | 1988-07-13 | Efamol Holdings | Essential fatty acid compositions |
GB8906369D0 (en) * | 1989-03-20 | 1989-05-04 | Tisdale Michael J | Eicosapentaenoic acid |
CH678181A5 (pt) * | 1989-05-22 | 1991-08-15 | Nestle Sa | |
GB9001121D0 (en) * | 1990-01-18 | 1990-03-21 | Efamol Holdings | Efa compositions and therapy |
DK0457950T3 (da) * | 1990-05-23 | 1994-03-07 | Nestle Sa | Anvendelse af stearidonsyre til behandling af inflammatorisk betingede sygdomme |
JP3400466B2 (ja) | 1991-10-28 | 2003-04-28 | 日本水産株式会社 | 高純度エイコサペンタエン酸またはそのエステルの製造方法 |
GB9224809D0 (en) | 1992-11-26 | 1993-01-13 | Scotia Holdings Plc | Schizophrenia |
GB9519661D0 (en) * | 1995-09-27 | 1995-11-29 | Scotia Holdings Plc | Fatty acid treatment |
KR20060061409A (ko) * | 1996-10-11 | 2006-06-07 | 스카리스타 리미티드 | 에이코사펜타엔산 및/또는 스테아리돈산을 포함하여이루어지는 오일 |
US6590846B2 (en) * | 1999-05-21 | 2003-07-08 | Matsushita Electric Industrial Co., Ltd. | Recordable optical disk |
-
1997
- 1997-10-07 KR KR1020067009861A patent/KR20060061409A/ko not_active Application Discontinuation
- 1997-10-07 CN CN97198908A patent/CN1109543C/zh not_active Expired - Fee Related
- 1997-10-07 CZ CZ19991154A patent/CZ293704B6/cs not_active IP Right Cessation
- 1997-10-07 DE DE69720787T patent/DE69720787T2/de not_active Expired - Lifetime
- 1997-10-07 TR TR1999/00786T patent/TR199900786T2/xx unknown
- 1997-10-07 ES ES97944022T patent/ES2195175T3/es not_active Expired - Lifetime
- 1997-10-07 WO PCT/GB1997/002738 patent/WO1998016216A1/en not_active Application Discontinuation
- 1997-10-07 PT PT97944022T patent/PT956013E/pt unknown
- 1997-10-07 SK SK448-99A patent/SK285210B6/sk not_active IP Right Cessation
- 1997-10-07 US US09/284,231 patent/US6331568B1/en not_active Expired - Lifetime
- 1997-10-07 IL IL12936797A patent/IL129367A0/xx active IP Right Grant
- 1997-10-07 CA CA002268257A patent/CA2268257C/en not_active Expired - Fee Related
- 1997-10-07 NZ NZ334852A patent/NZ334852A/en not_active IP Right Cessation
- 1997-10-07 BR BR9713479-1A patent/BR9713479A/pt not_active Application Discontinuation
- 1997-10-07 JP JP51808698A patent/JP4151853B2/ja not_active Expired - Fee Related
- 1997-10-07 AU AU45667/97A patent/AU731692C/en not_active Ceased
- 1997-10-07 KR KR1019997003079A patent/KR100657642B1/ko not_active IP Right Cessation
- 1997-10-07 DK DK97944022T patent/DK0956013T3/da active
- 1997-10-07 PL PL97333423A patent/PL190181B1/pl not_active IP Right Cessation
- 1997-10-07 ID IDW990162A patent/ID21473A/id unknown
- 1997-10-07 AT AT97944022T patent/ATE236627T1/de active
- 1997-10-07 EP EP97944022A patent/EP0956013B1/en not_active Expired - Lifetime
- 1997-10-09 TW TW086114830A patent/TW429145B/zh not_active IP Right Cessation
-
1999
- 1999-03-30 IS IS5017A patent/IS2180B/is unknown
- 1999-04-06 NO NO19991635A patent/NO326926B1/no not_active IP Right Cessation
- 1999-11-26 HK HK99105486A patent/HK1020316A1/xx not_active IP Right Cessation
-
2001
- 2001-09-18 US US09/956,739 patent/US6624195B2/en not_active Expired - Fee Related
- 2001-09-18 US US09/956,509 patent/US20020065319A1/en not_active Abandoned
-
2003
- 2003-05-02 US US10/428,020 patent/US20040014810A1/en not_active Abandoned
- 2003-07-11 US US10/617,184 patent/US20040048927A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR9713479A (pt) | Preparação farmacêutica compreendendo ácido eicosapentaenóico e/ou ácido estearidÈnico. | |
ES2053990T3 (es) | Composiciones de acidos grasos esenciales. | |
NO940277L (no) | Triglycerider og blandinger av slike | |
KR940018091A (ko) | 불포화 지방산을 포함하는 처방 | |
FR2754820B1 (fr) | Le (-)hydroxycitrate de magnesium, procede de preparation, applications, et compositions notamment pharmaceutiques le renfermant | |
MY109928A (en) | Fatty acid treatment | |
IS6644A (is) | Meðferðarblöndur fitusýra | |
NZ299464A (en) | Use of gamma linolenic or dihomogamma linolenic acid in the treatment of Huntington's Chorea | |
DE60000133D1 (de) | Essentielle fettsäuren zur vorbeugung von kardiovaskulären anfällen | |
YU89891A (sh) | SMEŠE TGF-beta | |
PT774962E (pt) | Utilizacao de dha como uma composicao farmaceutica | |
AU1821888A (en) | Treatment or prevention of memory loss using essential fatty acid compositions | |
ES2171535T3 (es) | Producto nutritivo utilizado en el tratamiento de la colitis ulcerosa y su uso. | |
DE60008127D1 (de) | Diät mit hohem lipidgehalt | |
ID15895A (id) | Formulasi untuk menurunkan kolesterol darah dan penyerapan lemak berbagai fungsi | |
NO932984L (no) | Fettsyrebehandling | |
MY129218A (en) | Pharmaceutical preparation comprising eicosapentaenoic acid and/or stearidonic acid | |
HUP0000419A2 (hu) | Eikozapentaénsavat és/vagy sztearidonsavat tartalmazó gyógyászati készítmény | |
TH58453B (th) | การบำบัดของกรดไขมัน | |
TH15810A (th) | สูตรผสมที่มีกรดแฟททีชนิดไม่อิ่มตัว | |
TH58453A (th) | การบำบัดของกรดไขมัน |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25G | Requested change of headquarter approved |
Owner name: SCOTIA HOLDINGS PLC (GB) Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 049365/RJ DE 03/09/2003. |
|
B25A | Requested transfer of rights approved |
Owner name: SCARISTA LIMITED (GB) Free format text: TRANSFERIDO DE: SCOTIA HOLDINGS PLC |
|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AO NAO REOLHIMENTO DA 5A ANUIDADE. |
|
B08H | Application fees: decision cancelled [chapter 8.8 patent gazette] |
Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1877 DE 26/12/2006 POR TER SIDO APRESENTADA PAPELETA DE ESCLARECIMENTO. |
|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: INDEFERO O PRESENTE PEDIDO DE PATENTE DE ACORDO COM ART. 8O DA LPI. |
|
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL. |